Despite achieving an entire reaction with optimum induction therapy, nominal residual condition often persists, necessitating consolidation therapy to mitigate the risk of relapse by reducing residual disease. In individuals who may have received seven+3 induction therapy, consolidation therapy is initiated with large-dose cytarabine, also referre